Browse every published article, from the latest research to earlier analysis. Use the page numbers below to explore the complete archive.
A severe infection case described persistent seizure activity during several medicines and attenuation after a paralytic was added. Motor suppression alone does not establish that cerebral seizure activity stopped.
A case report described only modest improvement in severe restlessness during multidrug treatment. It did not establish diazepam as an effective standalone treatment for the presentation.
A six-patient series described better mask acceptance during dexmedetomidine treatment. Its favorable respiratory narrative was not a controlled comparative safety result.
A small mortality-model study used subsequent treatment burden as a predictor. A score containing first-week information should not be described as entirely admission-based.
A laboratory surveillance analysis classified some detections as nonprescribed. That classification required clinical information beyond the analytical result itself.
A center comparison found different cerebral oxygenation and EEG patterns under midazolam-based and sevoflurane-based care. The groups differed beyond anesthetic choice.
A caregiver-interview study showed that a simple-looking regimen can still trigger medication-safety concerns. Potential risks were not the same as documented drug injuries.
A laboratory study correlated midazolam metabolism with ibrutinib-metabolite formation. It did not test a clinical interaction caused by giving both medicines together.
A hospital study associated benzodiazepines with pneumonia among antipsychotic-treated patients. Matching and adjustment did not establish a single-drug cause.
A case report suspected a medication-associated movement disorder and described improvement under two drugs. It did not establish clonazepam’s independent effect.
A veterinary case described uncomplicated recovery under a combined anesthetic. It did not establish that midazolam alone provided adequate anesthesia or cerebral protection.
A rat study tested prolonged saracatinib after standard countermeasures including midazolam. Favorable inflammation and seizure findings did not extend to every behavioral endpoint.
A linked national study measured dispensing prevalence over a defined window. Its hypnotic category and broader psychotropic percentage should not be relabeled as benzodiazepine-only use.
A machine-learning study achieved moderate delirium prediction using clinical and laboratory data. A selected benzodiazepine feature was not a causal estimate of drug harm.
A 218-resident medication study used software and several screening criteria. The resulting flags were review prompts, not counts of proven benzodiazepine harm.
A cross-sectional study found benzodiazepine use associated with polysubstance-use disorder in bipolar patients. It could not determine which came first.
A retrospective MRI-sedation study evaluated a combined regimen. It should not be described as evidence that dexmedetomidine alone replaced benzodiazepines.
A naturalistic borderline-personality-disorder study found reduced medication burden among skills-training participants. Participation was not randomized, and reduced prescribing was not itself a functional outcome.
A plant-extract experiment found anticonvulsant effects sensitive to flumazenil. The combination result did not establish a safe human interaction with diazepam.
A prescribing study found benzodiazepine derivatives among common drug groups in patients with polypharmacy. Its percentages did not describe all Spanish adults.
A before-and-after comparison found shorter scanning and fewer complications with dexmedetomidine–ketamine. The protocol change extended beyond replacing midazolam.
A child improved during a lengthy course after cyclosporine was stopped and psychiatric treatment introduced. The sequence did not isolate lorazepam’s independent effect.
A European adverse-report analysis examined misuse, dependence, and withdrawal for Z-drugs. Its reporting ratios were not exposure-adjusted clinical risks.
A rescued chimpanzee recovered from clinically diagnosed generalized tetanus under a coordinated regimen. The outcome cannot be assigned to diazepam alone.
A historical treatment review discussed several mechanisms and adjuncts. Benzodiazepines did not replace treatment of the wider cholinergic syndrome.
A flavonoid study combined seizure outcomes with molecular measurements. Its reported potentiation did not establish safe clinical augmentation of clonazepam.
A laboratory study found that a modified enterocyte preparation retained several metabolic activities. Its midazolam assay was a probe of intestinal metabolism, not a clinical sedation experiment.
A small controlled study compared benzodiazepine treatment, cupping, and a wait list. Shared imaging changes did not establish identical mechanisms or therapeutic equivalence.
A systematic-review protocol asked whether alpha-2 agonist evidence applied to brain-injured ventilated patients. It did not report completed comparative results against benzodiazepines.
A medicinal-chemistry review discussed AMPA inhibition by 2,3-benzodiazepines. The chemical-family name should not be treated as proof of conventional GABA-site sedative action.